PRODUCTS
‹
›
‹
›
Product name: Fexolinetant,Birinapant
CAS No.: 1629229-37-3
MF: C16H15FN6OS
M.W.: 358.39
Capacity: 10KG/M
Usage: R&D&Pipeline
INQUIRY NOW
■ Description
Description：Fezolinetant is an oral small molecule neurokinin-3 receptor (NK3R) antagonist developed by Astellas Pharma Inc. for the treatment of moderate to severe vasoconstrictive symptoms (VMS) or menopausal hot flashes. Fezolinetant is a non hormonal strategy that regulates neuronal activity related to temperature regulation by inhibiting NK3R mediated signaling in the central nervous system, thereby reducing the frequency and severity of VMS.
Origin：Fezolinetant was first approved in the United States in May 2023 for the treatment of moderate to severe vasoconstrictive symptoms (VMS) caused by menopause.
■ Message
Related Products
Leave A Message
If you are interested in our products and want to know more details, please leave a message here, we will reply you as soon as we can.